Smith & Nephew PLC ADR (SNN): Price and Financial Metrics


Smith & Nephew PLC ADR (SNN): $22.63

0.68 (+3.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNN POWR Grades

  • Value is the dimension where SNN ranks best; there it ranks ahead of 96.42% of US stocks.
  • SNN's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • SNN's current lowest rank is in the Momentum metric (where it is better than 30.28% of US stocks).

SNN Stock Summary

  • SNN has a market capitalization of $9,772,504,467 -- more than approximately 84.64% of US stocks.
  • Revenue growth over the past 12 months for SMITH & NEPHEW PLC comes in at 1.44%, a number that bests 25.22% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SNN comes in at 6.56% -- higher than that of 74.96% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SMITH & NEPHEW PLC are IOSP, TFX, MGIC, PNR, and BRC.
  • SNN's SEC filings can be seen here. And to visit SMITH & NEPHEW PLC's official web site, go to www.smith-nephew.com.

SNN Valuation Summary

  • In comparison to the median Healthcare stock, SNN's price/earnings ratio is 3.06% lower, now standing at 19.
  • Over the past 243 months, SNN's EV/EBIT ratio has gone down 5.3.

Below are key valuation metrics over time for SNN.

Stock Date P/S P/B P/E EV/EBIT
SNN 2022-09-23 1.9 1.8 19.0 18.6
SNN 2022-09-22 2.0 1.9 19.4 18.8
SNN 2022-09-21 2.0 1.9 19.5 18.9
SNN 2022-09-20 2.0 2.0 20.1 19.4
SNN 2022-09-19 2.1 2.0 20.4 19.6
SNN 2022-09-16 2.1 2.0 20.5 19.7

SNN Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 7.82%.
  • Its 5 year net income to common stockholders growth rate is now at -23.47%.
  • Its 4 year net income to common stockholders growth rate is now at -23.47%.
Over the past 30 months, SNN's revenue has gone up $74,000,001.

The table below shows SNN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 5,212 1,048 524
2021-12-31 5,212 1,048 524
2021-12-31 5,212 1,048 524
2021-06-30 4,560.001 972.0003 448.0001
2020-12-31 4,560 972 448
2020-12-31 4,560 972 448

SNN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SNN has a Quality Grade of B, ranking ahead of 77.5% of graded US stocks.
  • SNN's asset turnover comes in at 0.445 -- ranking 108th of 186 Medical Equipment stocks.
  • HOLX, TTOO, and BIOL are the stocks whose asset turnover ratios are most correlated with SNN.

The table below shows SNN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-03 0.445 0.694 0.050
2020-12-31 0.449 0.694 0.051
2020-12-31 0.449 0.694 0.051
2020-06-27 0.556 0.740 0.146
2019-12-31 0.592 0.740 0.174
2019-12-31 0.592 0.740 0.174

SNN Stock Price Chart Interactive Chart >

Price chart for SNN

SNN Price/Volume Stats

Current price $22.63 52-week high $37.28
Prev. close $21.95 52-week low $21.77
Day low $21.95 Volume 1,291,200
Day high $22.72 Avg. volume 943,825
50-day MA $25.31 Dividend yield 3.98%
200-day MA $30.35 Market Cap 9.85B

Smith & Nephew PLC ADR (SNN) Company Bio


Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The Company operates in two segments: Advanced Surgical Devices and Advanced Wound Management. The company was founded in 1856 and is based in London, the United Kingdom.


SNN Latest News Stream


Event/Time News Detail
Loading, please wait...

SNN Latest Social Stream


Loading social stream, please wait...

View Full SNN Social Stream

Latest SNN News From Around the Web

Below are the latest news stories about SMITH & NEPHEW PLC that investors may wish to consider to help them evaluate SNN as an investment opportunity.

Smith+Nephew Academy expands global access to professional medical education through virtual reality and other advanced simulation technologies

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it is expanding the reach of its medical education curriculum through a suite of advanced simulation technologies. Healthcare professionals can now conveniently access core orthopaedic, robotics and sports medicine procedural skills-training using virtual and augmented reality, haptics, and 3D interactive gaming at every Smith+Nephew Academy centre of excellence around the world.

Yahoo | September 21, 2022

Smith+Nephew launches OR3O™ Dual Mobility System in Japan for use in primary and revision hip arthroplasty

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its OR3O Dual Mobility System for use in primary and revision hip arthroplasty in Japan. Compared with traditional solutions, dual mobility implants have a small diameter femoral head that locks into a larger polyethylene insert - increasing stability, reducing dislocation risk, and offering improved range of motion.2

Yahoo | September 19, 2022

Smith & Nephew's Implant Shows 86% Reduction In Re-Tear Rates After Shoulder Surgery

Smith & Nephew plc (NYSE: SNN) announced new data furthering several published studies supporting the use of its REGENETEN Bioinductive Implant in rotator cuff repair. The REGENETEN Bioinductive Implant is part of Smith & Nephew's Advanced Healing Solutions portfolio. The goal of rotator cuff repair surgery is to help restore the shoulder's function and flexibility and relieve the pain that other treatments can't control. Also Read: Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds H

Yahoo | September 14, 2022

New randomized controlled trial shows that addition of Smith+Nephew's REGENETEN™ Bioinductive Implant delivers 86% reduction in rotator cuff re-tear rates at 12 months

Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published studies supporting the use of its REGENETEN Bioinductive Implant in rotator cuff repair. Interim analysis from a randomized controlled trial (RCT) shows a significant reduction in the re-tear rate of full-thickness rotator cuff repairs when using the REGENETEN Bioinductive Implant.

Yahoo | September 14, 2022

Smith & Nephew plc (LON:SN.) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

It is hard to get excited after looking at Smith & Nephew's (LON:SN.) recent performance, when its stock has declined...

Yahoo | September 12, 2022

Read More 'SNN' Stories Here

SNN Price Returns

1-mo -3.73%
3-mo -18.09%
6-mo -29.04%
1-year -33.45%
3-year -49.43%
5-year -30.66%
YTD -32.89%
2021 -16.26%
2020 -10.45%
2019 30.78%
2018 8.84%
2017 18.54%

SNN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNN Dividend History

Continue Researching SNN

Here are a few links from around the web to help you further your research on Smith & Nephew Plc's stock as an investment opportunity:

Smith & Nephew Plc (SNN) Stock Price | Nasdaq
Smith & Nephew Plc (SNN) Stock Quote, History and News - Yahoo Finance
Smith & Nephew Plc (SNN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5591 seconds.